CAR-T cell therapy represents a groundbreaking approach to cancer treatment, utilising genetically modified immune cells, sourced from either the patient or donors, to target and destroy cancer cells via a Chimeric Antigen Receptor (CAR). While CAR-T therapies mark a significant advancement in therapeutics, further research is required, particularly for solid tumours and in broader disease applications. Therefore, we are proud to supply CAR-T specific research tools to aid advancements in this area.
CAR-T research tools from BPS Bioscience
To propel your CAR-T cell research forward, BPS Bioscience offers a range of products perfectly designed for CAR-T research, which includes a collection of TCR, B2M and CIITA knockout cell lines ideal for modelling potentially universal CAR-T cells. The cell line engineering experts at BPS Bioscience specialise in the development of cell lines expressing common CAR targets, such as BCMA, CD19 and CD20, many of which include the luciferase reporter for simple monitoring.
A bespoke solution to your CAR-T research needs
BPS Bioscience also offer comprehensive custom CAR-T development services, encompassing CAR design, cellular functional validation, and expansion. Leveraging their proficiency in lentivirus production and cellular engineering, we ensure swift and dependable results to accelerate your research with milestone updates throughout the development process.
Materials for download
BPS Bioscience CAR-T tools brochure
Get in touch with our team
Contact our BPS Bioscience specialists for a quick discussion on how we can help meet your specific CAR-T research needs.
Products
Note: product availability depends on country - see product detail page.
Details | Cat number & supplier | Size | Price |
B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line BPS-78363 · BPS Bioscience | BPS-78363 BPS Bioscience |
2 vials |
£11768.00
2 vials
view
|
B2M Knockout Jurkat Cell Line BPS-78342 · BPS Bioscience | BPS-78342 BPS Bioscience |
2 vials |
£6894.00
2 vials
view
|
CD19 / CD20 / Firefly Luciferase CHO Cell Line BPS-78186 · BPS Bioscience | BPS-78186 BPS Bioscience |
2 vials |
£11137.00
2 vials
view
|
TCR/B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line BPS-78557 · BPS Bioscience | BPS-78557 BPS Bioscience |
2 vials |
£17707.00
2 vials
view
|
TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line BPS-78556 · BPS Bioscience | BPS-78556 BPS Bioscience |
2 vials |
£12945.00
2 vials
view
|
TCR/B2M Knockout Jurkat Cell Line BPS-78552 · BPS Bioscience | BPS-78552 BPS Bioscience |
2 vials |
£9169.00
2 vials
view
|
B2M/CIITA Double Knockout THP-1 Cell Line BPS-78391 · BPS Bioscience | BPS-78391 BPS Bioscience |
2 vials |
£10076.00
2 vials
view
|
CD8+ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line BPS-78757 · BPS Bioscience | BPS-78757 BPS Bioscience |
2 vials |
£16970.00
2 vials
view
|
Anti-CD19 CAR-T Cells BPS-78171-1 · BPS Bioscience | BPS-78171-1 BPS Bioscience |
1 vial |
£1692.00
1 vial
view
|
Anti-BCMA CAR-T Cells BPS-78660-1 · BPS Bioscience | BPS-78660-1 BPS Bioscience |
1 vial |
£1692.00
1 vial
view
|
Anti-BCMA Antibody BPS-101219 · BPS Bioscience | BPS-101219 BPS Bioscience |
100 µg |
£313.00
100 µg
view
|
CIITA (Human) CRISPR/Cas9 Lentivirus (Non-integrating) BPS-78434 · BPS Bioscience | BPS-78434 BPS Bioscience |
2 x 500 µl |
£1056.00
2 x 500 µl
view
|
CIITA (Human) CRISPR/Cas9 Lentivirus (Integrating) BPS-78435 · BPS Bioscience | BPS-78435 BPS Bioscience |
2 x 500 µl |
£844.00
2 x 500 µl
view
|
Anti-CD19/CD22 Bispecific CAR Lentivirus (Clones FMC63/m971 ScFv-CD8-4-1BB-CD3ζ) BPS-78609 · BPS Bioscience | BPS-78609 BPS Bioscience |
50 µl |
£1162.00
50 µl
view
|
B2M (Human) CRISPR/Cas9 Lentivirus (Integrating) BPS-78340 · BPS Bioscience | BPS-78340 BPS Bioscience |
2 x 500 µl |
£844.00
2 x 500 µl
view
|